Navigation Links
Akaza Research Releases New Version of OpenClinica Electronic Data Capture (EDC) Software; Targets Industry Clinical Trials
Date:9/19/2008

OpenClinica 2.5 represents a significant milestone for the growing open source clincial trials software. This release contains a host of improvements particularly oriented towards the needs of regulated industry sponsored clinical trials.

Cambridge, MA (PRWEB) September 19, 2008 -- Akaza Research announces the availability of OpenClinica 2.5, the popular open source http://www.openclinica.org/section.php?sid=1 [clinical trials software]. This release marks a major milestone for users of OpenClinica by adding a host of features, many of which are designed to better support regulated industry sponsored clinical trials.

OpenClinica 2.5 is freely available for download at http://www.openclinica.org.

Among the numerous improvements that comprise this release are:

-   New study monitoring and query management tools and reports
-   Import of data from external sources
-   Enhanced eCRF features, including scoring, multivariate edit checks, and rules
-   User roles for monitors and data managers
-   Electronic signature capabilities
-   Improved auditing and logging capabilities
-   Simpler CRF upload

In addition, this release provides a number of architectural enhancements:

-   Faster performance and improved scalability
-   Out-of-the box support for the Oracle database
-   Translation into 3 new languages: French, Italian, and Portuguese

"Many thanks to our partners in the OpenClinica community who have contributed to this substantial release," said Paul Galvin, who manages OpenClinica development for Akaza Research. Galvin states that a growing proportion of OpenClinica's improvements are coming from community contributions. "Our development team is spending more and more time collaborating with 3rd-party developers who provide code improvements. Just as valuable are the contributions from a core of dedicated end-users who provide ideas, feedback, and testing from the start of development through the final beta and release candidates."

Akaza Research places code contributions it receives through rigorous vetting and validation procedures to ensure the open source software it distributes meet the quality and regulatory demands of the clinical trials industry. According to Akaza this version of OpenClinica has been more heavily tested than any before. Users of OpenClinica Enterprise, the commercial distribution of the OpenClinica source code, will have access to more than 260 test cases and the reports resulting from thousands of hours of testing.

The release of OpenClinica 2.5 also marks a proud day for Cal Collins, Akaza's CEO. "There is tremendous excitement and anticipation among OpenClinica users for this release, and they will not be disappointed." When asked what he feels is most significant about this release, Collins replied: "Version 2.5 is an excellent demonstration of how a motivated open source community can produce world-class enterprise software."

Akaza Research will be conducting a webinar to present OpenClinica on October 7th, 2008. Registration for this event is available here:

- https://www2.gotomeeting.com/register/974214354 [Webinar @ 19:00 - 20:30 (GMT -5:00)]
- https://www2.gotomeeting.com/register/653567155 [Webinar @ 9:30 - 11:00 (GMT - 5:00)]


About OpenClinica®
OpenClinica is open source software for electronic data capture (EDC) and clinical data management. It facilitates protocol configuration, design of case report forms, clinical data capture, and study/data management. OpenClinica supports HIPAA and 21 CFR Part 11 regulations and is designed as a lightweight, standards-based, extensible, and modular platform. All versions of OpenClinica are available for download at http://www.OpenClinica.org.

About Akaza Research®
Akaza Research, the leading provider of open source clinical trial software, is headquartered in Cambridge, Massachusetts. Supported by the National Institutes of Health (NIH), Akaza has developed and commercialized OpenClinica, the preeminent open source clinical trial data capture and management software platform. Akaza brings Open Source Software (OSS) into the mainstream of the clinical research enterprise by making robust, flexible, standards-based systems accessible for all types of clinical research. Akaza Research provides OpenClinica support, training, and consulting services to its customers worldwide. See http://www.akazaresearch.com.

# # #

Read the full story at http://www.prweb.com/releases/clinicaltrialssoftware/electronicdatacapture/prweb1356434.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related biology technology :

1. eResearchTechnology, Inc. to Present at the UBS Global Life Sciences Conference on September 23rd, 2008
2. Peptimmune Presentation at Upcoming World Congress on Treatment and Research in Multiple Sclerosis
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
5. $1.6 Million Agreement to Accelerate Fragile X Research, Inspire Hope
6. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
7. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
8. Johnson & Johnson Honors 2008 Recipients of The Dr. Paul Janssen Award for Biomedical Research
9. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
10. OncologySTAT Advisors Name Years Top Developments in Cancer Treatment and Research
11. Dartmouth researchers advance cellulosic ethanol production
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Akaza Research Releases New Version of OpenClinica Electronic Data Capture (EDC) Software; Targets Industry Clinical Trials 
(Date:12/8/2016)... Francisco, CA (PRWEB) , ... December 08, 2016 ... ... Oculus as finalists in the World Technology Awards. uBiome is one of just ... received across all categories. , In addition to uBiome, companies nominated as finalists ...
(Date:12/8/2016)... 8, 2016  Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... on developing and commercializing products to treat rare ... announced today the long-term follow-up data from its ... first-in-class Innate Defense Regulator (IDR), in the treatment ... cancer patients undergoing chemoradiation therapy (CRT).  The additional ...
(Date:12/8/2016)... TAMPA, Fla. , Dec. 8, 2016 /PRNewswire/ ... biopharmaceutical company that discovers, develops and plans to ... today that its shares of common stock were approved ... stock will begin trading on the OTCQX, effective ... To qualify for the OTCQX market, companies must ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
Breaking Biology Technology:
(Date:11/30/2016)... Poland , Nov. 30, 2016 Not many of us realize that ... aspects of recovery so we need to do it well. Inadequate sleep levels have ... high blood pressure, stroke, diabetes, and even cancer. Maybe now is the ... present that could help them to manage their sleep quality? ... ...
(Date:11/29/2016)... 2016 Nearly one billion matches per second with ... ... DERMALOG is Germany's largest ... Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System ...
(Date:11/22/2016)... Nov. 22, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... Healthcare and Life Sciences Awards as "Most Outstanding ... an unprecedented year of recognition and growth for MedNet, ... 15 years. iMedNet ™ , ...
Breaking Biology News(10 mins):